Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Authors:
- Evandro de AzambujaEAEvandro de Azambuja
- Marion J. ProcterMPMarion J. Procter
- Dirk J. van VeldhuisenDVDirk J. van Veldhuisen
- Dominique Agbor-TarhDADominique Agbor-Tarh
- Otto Metzger-FilhoOMOtto Metzger-Filho
- Jutta SteinseiferJSJutta Steinseifer
- Michael UntchMUMichael Untch
- Ian E. SmithISIan E. Smith
- Luca GianniLGLuca Gianni
- Jose BaselgaJBJose Baselga
- Christian JackischCJChristian Jackisch
- David A. CameronDCDavid A. Cameron
- 10 July 2014
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (20) , 2159-2165
Abstract
Purpose: To document the rate and outcome of trastuzumab-associated cardiac dysfunction in patients following 1 or 2 years of adjuvant therapy. Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-arm, randomized trial comparing 2 years or 1 year of trastuzumab with observation in 5,102 patients with human epidermal growth factor receptor 2 (HER2) –positive early-stage breast cancer. Cardiac function was closely monitored. Eligible patients had left ventricular ejection fraction (LVEF) ≥ 55% at study entry following neoadjuvant chemotherapy with or without radiotherapy. This 8-year median follow-up analysis considered patients randomly assigned to 2 years or 1 year of trastuzumab or observation. Results: The as-treated safety population for 2 years of trastuzumab (n = 1,673), 1 year of trastuzumab (n = 1,682), and observation (n = 1,744) is reported. Cardiac adverse events leading to discontinuation of trastuzumab occurred in 9.4% of patients in the 2-year arm and 5.2% of patients in the 1-year arm. Cardiac death, severe congestive heart failure (CHF), and confirmed significant LVEF decrease remained low in all three arms. The incidence of severe CHF (0.8%, 0.8%, and 0.0%, respectively) and confirmed significant LVEF decrease (7.2%, 4.1%, and 0.9%, respectively) was significantly higher in the 2-year and 1-year trastuzumab arms compared with the observation arm. Severe CHF was the same for 2-year and 1-year trastuzumab. Of patients with confirmed LVEF decrease receiving 2-year trastuzumab, 87.5% reached acute recovery. Of patients with confirmed LVEF decrease receiving 1-year trastuzumab, 81.2% reached acute recovery. Conclusion: Long-term assessment at 8-year median follow-up confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy, and cardiac events were reversible in the vast majority of patients.Keywords
This publication has 20 references indexed in Scilit:
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factorsAnnals of Oncology, 2011
- Cardiotoxicity of anticancer treatments: what the cardiologist needs to knowNature Reviews Cardiology, 2010
- Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) TrialJournal of Clinical Oncology, 2010
- The Vulnerability of the Heart As a Pluricellular Paracrine OrganCirculation Research, 2010
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Requirement for neuregulin receptor erbB2 in neural and cardiac developmentNature, 1995